Platinum Rechallenge in Patients With Platinum-sensitive mTNBC
Platinum Retreated in Patients with Platinum Sensitive mTNBC
Metastatic Breast Cancer
DRUG: Vinorelbine|DRUG: DDP
Progression Free Survival (PFS), 6 weeks
Objective Response Rate (ORR), 6 weeks|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, 6 weeks|Overall Survival (OS), From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Platinum Retreated in Second- or Third-line Patients with Platinum Sensitive Metastatic Triple Negative Breast Cancer (randomised, phase II, NPN trial)